Metabolic control of immune tolerance in health and autoimmunity

Seminars in Immunology

Volumn 28, Issue 5, 2016, Pages 491-504

  Carbone, Fortunata ^a   La Rocca, Claudia ^a   De Candia, Paola ^b   Procaccini, Claudio ^a   Colamatteo, Alessandra ^c   Micillo, Teresa ^c   De Rosa, Veronica ^a,c   Matarese, Giuseppe ^a,d  

^a CNR   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c Unit di NeuroImmunologia   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Autoimmune diseases; Immune tolerance; Malnutrition; Metabolism; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOPOIETIN LIKE PROTEIN 2; COMPLEMENT FACTOR D; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN; RESISTIN; UNCLASSIFIED DRUG; AUTACOID;

ADIPOSE TISSUE; AUTOIMMUNITY; CELL METABOLISM; DIET RESTRICTION; DISEASE PREDISPOSITION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MALNUTRITION; METABOLIC REGULATION; MULTIPLE SCLEROSIS; NONHUMAN; OBESITY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; DIET; ENERGY METABOLISM; IMMUNITY; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; METABOLISM;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DIET; DISEASE SUSCEPTIBILITY; ENERGY METABOLISM; HUMANS; IMMUNE TOLERANCE; IMMUNITY; IMMUNOMODULATION; INFLAMMATION; INFLAMMATION MEDIATORS; MALNUTRITION; OBESITY; OVERWEIGHT;

EID: 85001038100     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2016.09.006     Document Type: Review

References (180)

1. [1] Ronti, T., Lupattelli, G., Mannarino, E., The endocrine function of adipose tissue: an update. Clin. Endocrinol.: Oxf. 64 (2006), 355–365.
2. [2] Leibel, R.L., Molecular physiology of weight regulation in mice and humans. Int. J. Obes.: Lond. 32 (2008), S98–108.
3. [3] Gesta, S., Tseng, Y.H., Kahn, C.R., Developmental origin of fat: tracking obesity to its source. Cell 131 (2007), 242–256.
4. [4] Sethi, J.K., Vidal-Puig, A.J., Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J. Lipid. Res. 48 (2007), 1253–1262.
5. [5] Wing, E.J., Magee, D.M., Barczynski, L.K., Acute starvation in mice reduces the number of T cells and suppresses the development of T-cell-mediated immunity. Immunology 63 (1988), 677–682.
6. [6] Blüher, M., Mantzoros, C.S., From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism 64 (2015), 131–145.
7. [7] Friedman, J.M., Halaas, J.L., Leptin and the regulation of body weight in mammals. Nature 395 (1998), 763–770.
8. [8] Matarese, G., La Cava, A., Sanna, V., Lord, G.M., Lechler, R.I., Fontana, S., et al. Balancing susceptibility to infection and autoimmunity: a role for leptin. Trends Immunol. 23 (2002), 182–187.
9. [9] Mancuso, P., Gottschalk, A., Phare, S.M., Peters-Golden, M., Lukacs, N.W., Huffnagle, G.B., Leptin-deficient mice exhibit impaired host defense in gram-negative pneumonia. J. Immunol. 168 (2002), 4018–4024.
10. [10] Loffreda, S., Yang, S.Q., Lin, H.Z., Karp, C.L., Brengman, M.L., Wang, D.J., et al. Leptin regulates proinflammatory immune responses. FASEB J. 12 (1998), 57–65.
11. [11] Gainsford, T., Willson, T.A., Metcalf, D., Handman, E., McFarlane, C., Ng, A., et al. Leptin can induce proliferation differentiation, and functional activation of hemopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 14564–14568.
12. [12] Macia, L., Delacre, M., Abboud, G., Ouk, T.S., Delanoye, A., Verwaerde, C., et al. Impairment of dendritic cell functionality and steady-state number in obese mice. J. Immunol. 177 (2006), 5997–6006.
13. [13] Tian, Z., Sun, R., Wei, H., Gao, B., Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem. Biophys. Res. Commun. 298 (2002), 297–302.
14. [14] Caldefie-Chezet, F., Poulin, A., Tridon, A., Sion, B., Vasson, M.P., Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action?. J. Leukoc. Biol. 69 (2001), 414–418.
15. [15] Caldefie-Chezet, F., Poulin, A., Vasson, M.P., Leptin regulates functional capacities of polymorphonuclear neutrophils. Free Radic. Res. 37 (2003), 809–814.
16. [16] Lord, G.M., Matarese, G., Howard, J.K., Baker, R.J., Bloom, S.R., Lechler, R.I., Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394 (1998), 897–901.
17. [17] La Cava, A., Matarese, G., The weight of leptin in immunity. Nat. Rev. Immunol. 4 (2004), 371–379.
18. [18] Howard, J.K., Lord, G.M., Matarese, G., Vendetti, S., Ghatei, M.A., Ritter, M.A., et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J. Clin. Invest. 104 (1999), 1051–1059.
19. [19] Sanchez-Margalet, V., Martín-Romero, C., Santos-Alvarez, J., Goberna, R., Najib, S., Gonzalez-Yanes, C., Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin. Exp. Immunol. 133 (2003), 11–19.
20. [20] Mandel, M.A., Mahmoud, A.A., Impairment of cell-mediated immunity in mutation diabetic mice (db/db). J. Immunol. 120 (1978), 1375–1377.
21. [21] Ozata, M., Ozdemir, I.C., Licinio, J., Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab. 84 (1999), 3686–3695.
22. [22] Farooqi, I.S., Matarese, G., Lord, G.M., Keogh, J.M., Lawrence, E., Agwu, C., et al. Beneficial effects of leptin on obesity T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110 (2002), 1093–1103.
23. [23] Wagner, N.M., Brandhorst, G., Czepluch, F., Lankeit, M., Eberle, C., Herzberg, S., et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity: Silver Spring 21 (2013), 461–468.
24. [24] Liu, Y., Yu, Y., Matarese, G., La Cava, A., Cutting edge: fasting-induced hypoleptinemia expands functional regulatory T cells in systemic lupus erythematosus. J. Immunol. 188 (2012), 2070–2073.
25. [25] De Rosa, V., Procaccini, C., Calì, G., Pirozzi, G., Fontana, S., Zappacosta, S., et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 26 (2007), 241–255.
26. [26] Procaccini, C., De Rosa, V., Galgani, M., Abanni, L., Calì, G., Porcellini, A., et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33 (2010), 929–941.
27. [27] Reis, B.S., Lee, K., Fanok, M.H., Mascaraque, C., Amoury, M., Cohn, L.B., et al. Leptin receptor signaling in T cells is required for Th17 differentiation. J. Immunol. 194 (2015), 5253–5260.
28. [28] Yu, Y., Liu, Y., Shi, F.D., Zou, H., Matarese, G., La Cava, A., Cutting edge: leptin-induced RORγt expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J. Immunol. 190 (2013), 3054–3058.
29. [29] Holcomb, I.N., Kabakoff, R.C., Chan, B., Baker, T.W., Gurney, A., Henzel, W., et al. FIZZ1 a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 19 (2000), 4046–4055.
30. [30] Ghosh, S., Singh, A.K., Aruna, B., Mukhopadhyay, S., Ehtesham, N.Z., The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 305 (2003), 27–34.
31. [31] Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001), 307–312.
32. [32] Fain, J.N., Cheema, P.S., Bahouth, S.W., Lloyd Hiler, M., Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun. 300 (2003), 674–678.
33. [33] Janke, J., Engeli, S., Gorzelniak, K., Luft, F.C., Sharma, A.M., Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res. 10 (2002), 1–5.
34. [34] Degawa-Yamauchi, M., Bovenkerk, J.E., Juliar, B.E., Watson, W., Kerr, K., Jones, R., et al. Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab. 88 (2003), 5452–5455.
35. [35] Banerjee, R.R., Rangwala, S.M., Shapiro, J.S., Rich, A.S., Rhoades, B., Qi, Y., et al. Regulation of fasted blood glucose by resistin. Science 303 (2004), 1195–1198.
36. [36] Fu, Y., Luo, L., Luo, N., Garvey, W.T., Proinflammatory cytokine production and insulin sensitivity regulated by overexpression of resistin in 3T3-L1 adipocytes. Nutr. Metab.: Lond., 3, 2006.
37. [37] Bokarewa, M., Nagaev, I., Dahlberg, L., Smith, U., Tarkowski, A., Resistin an adipokine with potent proinflammatory properties. J. Immunol. 174 (2005), 5789–5795.
38. [38] Tarkowski, A., Bjersing, J., Shestakov, A., Bokarewa, M.I., Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J. Cell. Mol. Med. 14 (2010), 1419–1431.
39. [39] Collart, M.A., Baeuerle, P., Vassalli, P., Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol. Cell. Biol. 10 (1990), 1498–1506.
40. [40] Son, Y.M., Ahn, S.M., Kim, G.R., Moon, Y.S., Kim, S.H., Park, Y.M., et al. Resistin enhances the expansion of regulatory T cells through modulation of dendritic cells. BMC. Immunol., 11, 2010.
41. [41] Filkova, M., Haluzik, M., Gay, S., Senolt, L., The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin. Immunol. 133 (2009), 157–170.
42. [42] Kraszula, L., Jasińska, A., Eusebio, M., Kuna, P., Głąbiński, A., Pietruczuk, M., Evaluation of the relationship between leptin resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurol. Neurochir Pol. 46 (2012), 22–28.
43. [43] Johnston, A., Arnadottir, S., Gudjonsson, J.E., Aphale, A., Sigmarsdottir, A.A., Gunnarsson, S.I., et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br. J. Dermatol. 159 (2008), 342–350.
44. [44] Kocabas, H., Kocabas, V., Buyukbas, S., Melıkoglu, M.A., Sezer, I., Butun, B., The serum levels of resistin in ankylosing spondylitis patients: a pilot study. Rheumatol. Int. 32 (2012), 699–702.
45. [45] Boström, E.A., d'Elia, H.F., Dahlgren, U., Simark-Mattsson, C., Hasséus, B., Carlsten, H., et al. Salivary resistin reflects local inflammation in Sjögren's syndrome. J. Rheumatol. 35 (2008), 2005–2011.
46. [46] Tabata, M., Kadomatsu, T., Fukuhara, S., Miyata, K., Ito, Y., Endo, M., et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell. Metab. 10 (2009), 178–188.
47. [47] Kadomatsu, T., Endo, M., Miyata, K., Oike, Y., Diverse roles of ANGPTL2 in physiology and pathophysiology. Trends Endocrinol. Metab. 25 (2014), 245–254.
48. [48] Sasaki, Y., Ohta, M., Desai, D., Figueiredo, J.L., Whelan, M.C., Sugano, T., et al. Angiopoietin like protein 2 (ANGPTL2) promotes adipose tissue macrophage and T lymphocyte accumulation and leads to insulin resistance. PLoS One, 10, 2015, e0131176.
49. [49] Okada, T., Tsukano, H., Endo, M., Tabata, M., Miyata, K., Kadomatsu, T., et al. Synoviocyte-derived angiopoietin-like protein 2 contributes to synovial chronic inflammation in rheumatoid arthritis. Am. J. Pathol. 176 (2010), 2309–2319.
50. [50] Samal, B., Sun, Y., Stearns, G., Xie, C., Suggs, S., McNiece, I., Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14 (1994), 1431–1437.
51. [51] Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005), 426–430.
52. [52] Jia, S.H., Li, Y., Parodo, J., Kapus, A., Fan, L., Rotstein, O.D., Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Invest. 113 (2004), 1318–1327.
53. [53] Moschen, A.R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 178 (2007), 1748–1758.
54. [54] Ye, S.Q., Simon, B.A., Maloney, J.P., Zambelli-Weiner, A., Gao, L., Grant, A., et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am. J. Respir. Crit. Care Med. 171 (2005), 361–370.
55. [55] Koczan, D., Guthke, R., Thiesen, H.J., Ibrahim, S.M., Kundt, G., Krentz, H., et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur. J. Dermatol. 15 (2005), 251–257.
56. [56] Emamgholipour, S., Eshaghi, S.M., Hossein-nezhad, A., Mirzaei, K., Maghbooli, Z., Sahraian, M.A., Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease. PLoS One, 8, 2013, e76555.
57. [57] Waluga, M., Hartleb, M., Boryczka, G., Kukla, M., Zwirska-Korczala, K., Serum adipokines in inflammatory bowel disease. World J. Gastroenterol. 20 (2014), 6912–6917.
58. [58] Otero, M., Lago, R., Gomez, R., Lago, F., Dieguez, C., Gómez-Reino, J.J., et al. Changes in plasma levels of fat-derived hormones adiponectin leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65 (2006), 1198–1201.
59. [59] Brentano, F., Schorr, O., Ospelt, C., Stanczyk, J., Gay, R.E., Gay, S., et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 56 (2007), 2829–2839.
60. [60] Shapiro, L., Scherer, P.E., The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 8 (1998), 335–338.
61. [61] Maeda, K., Okubo, K., Shimomura, I., Funahashi, T., Matsuzawa, Y., Matsubara, K., cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun. 221 (1996), 286–289.
62. [62] Ryo, M., Nakamura, T., Kihara, S., Kumada, M., Shibazaki, S., Takahashi, M., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J 68 (2004), 975–981.
63. [63] Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., et al. Plasma concentrations of a novel adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20 (2000), 1595–1599.
64. [64] Ayina, C.N., Noubiap, J.J., Etoundi Ngoa, L.S., Boudou, P., Gautier, J.F., Mengnjo, M.K., et al. Association of serum leptin and adiponectin with anthropomorphic indices of obesity, blood lipids and insulin resistance in a Sub-Saharan African population. Lipids Health Dis., 15, 2016.
65. [65] Hui, X., Gu, P., Zhang, J., Nie, T., Pan, Y., Wu, D., et al. Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promoting M2 macrophage proliferation. Cell. Metab. 22 (2015), 279–290.
66. [66] Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama, A., Ouchi, N., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000), 1723–1732.
67. [67] Wolf, A.M., Wolf, D., Rumpold, H., Enrich, B., Tilg, H., Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 323 (2004), 630–635.
68. [68] Ohashi, K., Parker, J.L., Ouchi, N., Higuchi, A., Vita, J.A., Gokce, N., et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J. Biol. Chem. 285 (2010), 6153–6160.
69. [69] Wilk, S., Scheibenbogen, C., Bauer, S., Jenke, A., Rother, M., Guerreiro, M., et al. Adiponectin is a negative regulator of antigen-activated T cells. Eur. J Immunol. 41 (2011), 2323–2332.
70. [70] Okamoto, Y., Christen, T., Shimizu, K., Asano, K., Kihara, S., Mitchell, R.N., et al. Adiponectin inhibits allograft rejection in murine cardiac transplantation. Transplantation 88 (2009), 879–883.
71. [71] Tsang, J.Y., Li, D., Ho, D., Peng, J., Xu, A., Lamb, J., et al. Novel immunomodulatory effects of adiponectin on dendritic cell functions. Int. Immunopharmacol. 11 (2011), 604–609.
72. [72] Cheng, X., Folco, E.J., Shimizu, K., Libby, P., Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. J. Biol. Chem. 287 (2012), 36896–36904.
73. [73] Jung, M.Y., Kim, H.S., Hong, H.J., Youn, B.S., Kim, T.S., Adiponectin induces dendritic cell activation via PLCγ/JNK/NF-κB pathways, leading to Th1 and Th17 polarization. J. Immunol. 188 (2012), 2592–2601.
74. [74] Giles, J.T., Allison, M., Bingham, C.O. 3rd, Scott, W.M. Jr, Bathon, J.M., Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum. 61 (2009), 1248–1256.
75. [75] Piccio, L., Cantoni, C., Henderson, J.G., Hawiger, D., Ramsbottom, M., Mikesell, R., et al. Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. Eur. J. Immunol. 43 (2013), 2089–2100.
76. [76] Shibata, S., Tada, Y., Hau, C.S., Mitsui, A., Kamata, M., Asano, Y., et al. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nat. Commun., 6, 2015.
77. [77] White, R.T., Damm, D., Hancock, N., Rosen, B.S., Lowell, B.B., Usher, P., et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J. Biol. Chem. 267 (1992), 9210–9213.
78. [78] Cook, K.S., Groves, D.L., Min, H.Y., Spiegelman, B.M., A developmentally regulated mRNA from 3T3 adipocytes encodes a novel serine protease homologue. Proc. Natl. Acad. Sci. U. S. A. 82 (1985), 6480–6484.
79. [79] Cianflone, K., Xia, Z., Chen, L.Y., Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta 1609 (2003), 127–143.
80. [80] Lo, J.C., Ljubicic, S., Leibiger, B., Kern, M., Leibiger, I.B., Moede, T., et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell 158 (2014), 41–53.
81. [81] Natarajan, R., Hagman, S., Hämälainen, M., Leppänen, T., Dastidar, P., Moilanen, E., et al. Adipsin is associated with multiple sclerosis: a follow-up study of adipokines. Mult. Scler. Int., 2015, 2015.
82. [82] Hietaharju, A., Kuusisto, H., Nieminen, R., Vuolteenaho, K., Elovaara, I., Moilanen, E., Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin study. Eur. J. Neurol. 17 (2010), 332–334.
83. [83] Samaras, K., Botelho, N.K., Chisholm, D.J., Lord, R.V., Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity: Silver Spring 18 (2010), 884–889.
84. [84] Bruun, J.M., Lihn, A.S., Pedersen, S.B., Richelsen, B., Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab. 90 (2005), 2282–2289.
85. [85] Christadoss, P., Talal, N., Lindstrom, J., Fernandes, G., Suppression of cellular and humoral immunity to T-dependent antigens by calorie restriction. Cell. Immunol. 88 (1984), 1–8.
86. [86] Caulfield, L.E., de Onis, M., Blössner, M., Black, R.E., Undernutrition as an underlying cause of child deaths associated with diarrhea pneumonia, malaria, and measles. Am. J. Clin. Nutr. 80 (2004), 193–198.
87. [87] Procaccini, C., De Rosa, V., Galgani, M., Carbone, F., Cassano, S., Greco, D., et al. Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses. J. Immunol. 189 (2012), 2941–2953.
88. [88] González-Torres, C., González-Martínez, H., Miliar, A., Nájera, O., Graniel, J., Firo, V., et al. Effect of malnutrition on the expression of cytokines involved in Th1 cell differentiation. Nutrients 5 (2013), 579–593.
89. [89] González-Martínez, H., Rodríguez, L., Nájera, O., Cruz, D., Miliar, A., Domínguez, A., et al. Expression of cytokine mRNA in lymphocytes of malnourished children. J. Clin. Immunol. 28 (2008), 593–599.
90. [90] Saucillo, D.C., Gerriets, V.A., Sheng, J., Rathmell, J.C., Maciver, N.J., Leptin metabolically licenses T cells for activation to link nutrition and immunity. J. Immunol. 192 (2014), 136–144.
91. [91] Pászthy, B., Svec, P., Vásárhelyi, B., Túry, F., Mazzag, J., Tulassay, T., et al. Investigation of regulatory T cells in anorexia nervosa. Eur. J. Clin. Nutr. 61 (2007), 1245–1249.
92. [92] Taylor, A.K., Cao, W., Vora, K.P., De La Cruz, J., Shieh, W.J., Zaki, S.R., Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice. J. Infect. Dis. 207 (2013), 501–510.
93. [93] Pena-Cruz, V., Reiss, C.S., McIntosh, K., Sendai virus infection of mice with protein malnutrition. J. Virol. 63 (1989), 3541–3544.
94. [94] Chan, J., Tian, Y., Tanaka, K.E., Tsang, M.S., Yu, K., Salgame, P., Effects of protein calorie malnutrition on tuberculosis in mice. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 14857–14861.
95. [95] Iyer, S.S., Chatraw, J.H., Tan, W.G., Wherry, E.J., Becker, T.C., Ahmed, R., et al. Protein energy malnutrition impairs homeostatic proliferation of memory CD8T cells. J. Immunol. 188 (2012), 77–84.
96. [96] Chatraw, J.H., Wherry, E.J., Ahmed, R., Kapasi, Z.F., Diminished primary CD8T cell response to viral infection during protein energy malnutrition in mice is due to changes in microenvironment and low numbers of viral-specific CD8T cell precursors. J. Nutr. 138 (2008), 806–812.
97. [97] Shushimita, S., de Bruijn, M.J., de Bruin, R.W., Jzermans, J.N.I., Hendriks, R.W., Dor, F.J., Dietary restriction and fasting arrest B and T cell development and increase mature B and T cell numbers in bone marrow. PLoS One, 9, 2014, e87772.
98. [98] Nájera, O., González, C., Toledo, G., López, L., Ortiz, R., Flow cytometry study of lymphocyte subsets in malnourished and well-nourished children with bacterial infections. Clin. Diagn. Lab. Immunol. 11 (2004), 577–580.
99. [99] de Oliveira, D.C., Hastreiter, A.A., Mello, A.S., de Oliveira Beltran, J.S., Oliveira Santos, E.W., Borelli, P., et al. The effects of protein malnutrition on the TNF-RI and NF-κB expression via the TNF-α signaling pathway. Cytokine 69 (2014), 218–225.
100. [100] Piccio, L., Stark, J.L., Cross, A.H., Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J. Leukoc. Biol. 84 (2008), 940–948.
101. [101] Sanna, V., Di Giacomo, A., La Cava, A., Lechler, R.I., Fontana, S., Zappacosta, S., et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J. Clin. Invest. 111 (2003), 241–250.
102. [102] Hafström, I., Ringertz, B., Gyllenhammar, H., Palmblad, J., Harms-Ringdahl, M., Effects of fasting on disease activity, neutrophil function, fatty acid composition, and leukotriene biosynthesis in patients with rheumatoid arthritis. Arthritis Rheum. 31 (1988), 585–592.
103. [103] Iwashige, K., Kouda, K., Kouda, M., Horiuchi, K., Takahashi, M., Nagano, A., et al. Calorie restricted diet and urinary pentosidine in patients with rheumatoid arthritis. J. Physiol. Anthropol. Appl. Human Sci. 23 (2004), 19–24.
104. [104] Fraser, D.A., Thoen, J., Reseland, J.E., Førre, O., Kjeldsen-Kragh, J., Decreased CD4+ lymphocyte activation and increased interleukin-4 production in peripheral blood of rheumatoid arthritis patients after acute starvation. Clin. Rheumatol. 18 (1999), 394–401.
105. [105] Fernandes, G., Friend, P., Yunis, E.J., Good, R.A., Influence of dietary restriction on immunologic function and renal disease in (NZB × NZW) F1 mice. Proc. Natl. Acad. Sci. U. S. A. 75 (1978), 1500–1504.
106. [106] Shibolet, O., Alper, R., Avraham, Y., Berry, E.M., Ilan, Y., Immunomodulation of experimental colitis via caloric restriction: role of Nk1.1+ T cells. Clin. Immunol. 105 (2002), 48–56.
107. [107] Winer, S., Paltser, G., Chan, Y., Tsui, H., Engleman, E., Winer, D., et al. Obesity predisposes to Th17 bias. Eur. J. Immunol. 39 (2009), 2629–2635.
108. [108] Kleinewietfeld, M., Manzel, A., Titze, J., Kvakan, H., Yosef, N., Linker, R.A., et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496 (2013), 518–522.
109. [109] Hernandez, A.L., Kitz, A., Wu, C., Lowther, D.E., Rodriguez, D.M., Vudattu, N., et al. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J. Clin. Invest. 125 (2015), 4212–4222.
110. [110] Dominguez-Villar, M., Baecher-Allan, C.M., Hafler, D.A., Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat. Med. 17 (2011), 673–675.
111. [111] Sawcer, S., Franklin, R.J., Ban, M., Multiple sclerosis genetics. Lancet Neurol. 13 (2014), 700–709.
112. [112] Hedström, A.K., Lima Bomfim, I., Barcellos, L., Gianfrancesco, M., Schaefer, C., Kockum, I., et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 82 (2014), 865–872.
113. [113] Munger, K.L., Chitnis, T., Ascherio, A., Body size and risk of MS in two cohorts of US women. Neurology 73 (2009), 1543–1550.
114. [114] Hedström, A.K., Olsson, T., Alfredsson, L., High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 18 (2012), 1334–1336.
115. [115] Hedström, A.K., Olsson, T., Alfredsson, L., Body mass index during adolescence rather than childhood, is critical in determining MS risk. Mult. Scler. 22 (2016), 878–883.
116. [116] Kavak, K.S., Teter, B.E., Hagemeier, J., Zakalik, K., Weinstock-Guttman, B., New York state multiple sclerosis consortium, higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Mult. Scler. 21 (2015), 858–865.
117. [117] Langer-Gould, A., Brara, S.M., Beaber, B.E., Koebnick, C., Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 80 (2013), 548–552.
118. [118] Munger, K.L., Bentzen, J., Laursen, B., Stenager, E., Koch-Henriksen, N., Sørensen, T.I., et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult. Scler. 19 (2013), 1323–1329.
119. [119] Bovea, R., Musallama, A., Xiaa, Z., Barucha, N., Messinaa, S., Healya, B.C., et al. Longitudinal BMI trajectories in multiple sclerosis: sex differences in association with disease severity. Mult. Scler. Relat. Disord. 8 (2016), 136–140.
120. [120] Carrieri, P.B., Carbone, F., Perna, F., Bruzzese, D., La Rocca, C., Galgani, M., et al. Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate. Metabolism 64 (2015), 1112–1121.
121. [121] Matarese, G., Carrieri, P.B., La Cava, A., Perna, F., Sanna, V., De Rosa, V., et al. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 5150–5155.
122. [122] Carbone, F., De Rosa, V., Carrieri, P.B., Montella, S., Bruzzese, D., Porcellini, A., et al. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat. Med. 20 (2014), 69–74.
123. [123] Matarese, G., Di Giacomo, A., Sanna, V., Lord, G.M., Howard, J.K., Di Tuoro, A., et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J. Immunol. 166 (2001), 5909–5916.
124. [124] Matarese, G., Sanna, V., Di Giacomo, A., Lord, G.M., Howard, J.K., Bloom, S.R., et al. Leptin potentiates experimental autoimmune encephalomyelitis in SJL female mice and confers susceptibility to males. Eur. J. Immunol. 31 (2001), 1324–1332.
125. [125] De Rosa, V., Procaccini, C., La Cava, A., Chieffi, P., Nicoletti, G.F., Fontana, S., et al. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J. Clin. Invest. 116 (2006), 447–455.
126. [126] Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002), 500–508.
127. [127] Hernández Avila, M., Liang, M.H., Willett, W.C., Stampfer, M.J., Colditz, G.A., Rosner, B., et al. Reproductive factors, smoking, and the risk for rheumatoid arthritis. Epidemiology 1 (1990), 285–291.
128. [128] Cerhan, J.R., Saag, K.G., Criswell, L.A., Merlino, L.A., Mikuls, T.R., Blood transfusion alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. J. Rheumatol. 29 (2002), 246–254.
129. [129] Crowson, C.S., Matteson, E.L., Davis, J.M. 3rd, Gabriel, S.E., Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res.: Hoboken 65 (2013), 71–77.
130. [130] Lu, B., Hiraki, L.T., Sparks, J.A., Malspeis, S., Chen, C.Y., Awosogba, J.A., et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann. Rheum. Dis. 73 (2014), 1914–1922.
131. [131] Ajeganova, S., Andersson, M.L., Hafström, I., BARFOT Study Group, Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res.: Hoboken 65 (2013), 78–87.
132. [132] Stavropoulos-Kalinoglou, A., Metsios, G.S., Panoulas, V.F., Nevill, A.M., Jamurtas, A.Z., Koutedakis, Y., et al. Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. Clin. Rheumatol. 28 (2009), 439–444.
133. [133] Choe, J.Y., Bae, J., Lee, H., Park, S.H., Kim, S.K., Lack association of body mass index with disease activity composites of rheumatoid arthritis in Korean population: cross-sectional observation. Clin. Rheumatol. 33 (2014), 485–492.
134. [134] Olama, S.M., Senna, M.K., Elarman, M., Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. Rheumatol. Int. 32 (2012), 683–690.
135. [135] Tan, W., Wang, F., Zhang, M., Guo, D., Zhang, Q., He, S., High adiponectin and adiponectin receptor 1 expression in synovial fluids and synovial tissues of patients with rheumatoid arthritis. Semin. Arthritis Rheum. 38 (2009), 420–427.
136. [136] Senolt, L., Housa, D., Vernerová, Z., Jirásek, T., Svobodová, R., Veigl, D., et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann. Rheum. Dis. 66 (2007), 458–463.
137. [137] Wilkin, T.J., The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44 (2001), 914–922.
138. [138] Rasmussen, T., Stene, L.C., Samuelsen, S.O., Cinek, O., Wetlesen, T., Torjesen, P.A., et al. Maternal BMI before pregnancy, maternal weight gain during pregnancy, and risk of persistent positivity for multiple diabetes-associated autoantibodies in children with the high-risk HLA genotype: the MIDIA study. Diabetes Care 32 (2009), 1904–1906.
139. [139] Vlajinac, H., Sipetić, S., Marinković, J., Bjekić, M., Kocev, N., Sajić, S., The Belgrade childhood diabetes study—comparison of children with type 1 diabetes with their siblings. Paediatr. Perinat. Epidemiol. 20 (2006), 238–243.
140. [140] McKinney, P.A., Parslow, R., Gurney, K., Law, G., Bodansky, H.J., Williams, D.R., Antenatal risk factors for childhood diabetes mellitus; a case-control study of medical record data in Yorkshire UK. Diabetologia 40 (1997), 933–939.
141. [141] Arkkola, T., Kautiainen, S., Takkinen, H.M., Kenward, M.G., Nevalainen, J., Uusitalo, U., et al. Relationship of maternal weight status and weight gain rate during pregnancy to the development of advanced beta cell autoimmunity in the offspring: a prospective birth cohort study. Pediatr. Diabetes 12 (2011), 478–484.
142. [142] Robertson, L., Harrild, K., Maternal and neonatal risk factors for childhood type 1 diabetes: a matched case-control study. BMC Public Health, 10, 2010.
143. [143] Harder, T., Roepke, K., Diller, N., Stechling, Y., Dudenhausen, J.W., Plagemann, A., Birth weight, early weight gain, and subsequent risk of type 1 diabetes: systematic review and meta-analysis. Am. J. Epidemiol. 169 (2009), 1428–1436.
144. [144] Verbeeten, K.C., Elks, C.E., Daneman, D., Ong, K.K., Association between childhood obesity and subsequent Type 1 diabetes: a systematic review and meta-analysis. Diabet. Med. 28 (2011), 10–18.
145. [145] Harpsøe, M.C., Basit, S., Andersson, M., Nielsen, N.M., Frisch, M., Wohlfahrt, J., et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int. J. Epidemiol. 43 (2014), 843–855.
146. [146] Kibirige, M., Metcalf, B., Renuka, R., Wilkin, T.J., Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 26 (2003), 2865–2870.
147. [147] Dahlquist, G., Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 49 (2006), 20–24.
148. [148] Geyikli, I., Keskin, M., Kör, Y., Akan, M., Increased resistin serum concentrations in patientswith type 1 diabetes mellitus. J. Clin. Res. Pediatr. Endocrinol. 5 (2013), 189–193.
149. [149] Brown, J.E., Onyango, D.J., Dunmore, S.J., Resistin down-regulates insulin receptor expression, and modulates cell viability in rodent pancreatic beta-cells. FEBS Lett. 581 (2007), 3273–3276.
150. [150] Luna, R., Garcia-Mayor, R.V., Lage, M., Andrade, M.A., Barreiro, J., Pombo, M., et al. High serum leptin levels in children with type 1 diabetes mellitus: contribution of age, BMI, pubertal development and metabolic status. Clin. Endocrinol. Oxf. 51 (1999), 603–610.
151. [151] Kirel, B., Doğruel, N., Korkmaz, U., Kiliç, F.S., Ozdamar, K., Uçar, B., Serum leptin levels in type 1 diabetic and obese children: relation to insulin levels. Clin. Biochem. 33 (2000), 475–480.
152. [152] Verrotti, A., Basciani, F., Morgese, G., Chiarelli, F., Leptin levels in non-obese and obese children and young adults with type 1 diabetes mellitus. Eur. J. Endocrinol. 139 (1998), 49–53.
153. [153] Matarese, G., Sanna, V., Lechler, R.I., Sarvetnick, N., Fontana, S., Zappacosta, S., et al. Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes 51 (2002), 1356–1361.
154. [154] Habeeb, N.M., Youssef, O.I., Saab, A.A., El Hadidi, E.S., Adiponectin as a marker of complications in type I diabetes. Indian Pediatr. 49 (2012), 277–280.
155. [155] Forsblom, C., Thomas, M.C., Moran, J., Saraheimo, M., Thorn, L., Wadén, J., et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J. Intern. Med. 270 (2011), 346–355.
156. [156] Pang, T.T., Chimen, M., Goble, E., Dixon, N., Benbow, A., Eldershaw, S.E., et al. Inhibition of islet immunoreactivity by adiponectin is attenuated in human type 1 diabetes. J. Clin. Endocrinol. Metab. 98 (2013), 418–428.
157. [157] Wijesekara, N., Krishnamurthy, M., Bhattacharjee, A., Suhail, A., Sweeney, G., Wheeler, M.B., Adiponectin-induced ERK Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J. Biol. Chem. 285 (2010), 33623–33631.
158. [158] Seldin, M.F., The genetics of human autoimmune disease: a perspective on progress in the field and future directions. J. Autoimmun. 64 (2015), 1–12.
159. [159] Lindegård, B., Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (1986), 298–304.
160. [160] Armstrong, A.W., Harskamp, C.T., Armstrong, E.J., The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr. Diabetes, 2, 2012, e54.
161. [161] Kumar, S., Han, J., Li, T., Qureshi, A.A., Obesity waist circumference, weight change and the risk of psoriasis in US women. J. Eur. Acad. Dermatol. Venereol. 27 (2013), 1293–1298.
162. [162] Herron, M.D., Hinckley, M., Hoffman, M.S., Papenfuss, J., Hansen, C.B., Callis, K.P., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch. Dermatol. 141 (2005), 1527–1534.
163. [163] Duarte, G.V., Oliveira Mde, F., Cardoso, T.M., Follador, I., Silva, T.S., Cavalheiro, C.M., et al. Association between obesity measured by different parameters and severity of psoriasis. Int. J. Dermatol. 52 (2013), 177–181.
164. [164] Debbaneh, M., Millsop, J.W., Bhatia, B.K., Koo, J., Liao, W., Diet and psoriasis, part I: Impact of weight loss interventions. J. Am. Acad. Dermatol. 71 (2014), 133–140.
165. [165] Yin, Y., Choi, S.C., Xu, Z., Perry, D.J., Seay, H., Croker, B.P., et al. L. Normalization of CD4+ T cell metabolism reverses lupus. Sci. Trans. Med., 7, 2015, 274ra18.
166. [166] Yin, Y., Choi, S.C., Xu, Z., Zeumer, L., Kanda, N., Croker, B.P., et al. Glucose oxidation is critical for CD4+ T cell activation in a mouse model of systemic lupus erythematosus. J. Immunol. 196 (2016), 80–90.
167. [167] Ebers, G.C., Bulman, D.E., Sadovnick, A.D., Paty, D.W., Warren, S., Hader, W., et al. A population-based study of multiple sclerosis in twins. N. Engl. J. Med. 315 (1986), 1638–1642.
168. [168] Jones, H.H., Jones, H.H. Jr., Bunch, D., Biochemical studies in multiple sclerosis. Ann. Intern. Med. 33 (1950), 831–840.
169. [169] McArdle, B., Mackenzie, I.C., Webster, G.R., Studies on intermediate carbohydrate meatabolism in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 23 (1960), 127–132.
170. [170] Tisell, A., Leinhard, O.D., Warntjes, J.B., Aalt, A., Ö. Smedby, Landtblom, A.M., et al. Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. PLoS One, 8, 2013, e61817.
171. [171] Sarchielli, P., Greco, L., Floridi, A., Floridi, A., Gallai, V., Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch. Neurol. 60 (2003), 1082–1088.
172. [172] Regenold, W.T., Phatak, P., Makley, M.J., Stone, R.D., Kling, M.A., Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J. Neurol. Sci. 275 (2008), 106–112.
173. [173] De Rosa, V., Galgani, M., Porcellini, A., Colamatteo, A., Santopaolo, M., Zuchegna, C., et al. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat. Immunol. 16 (2015), 1174–1184.
174. [174] Shriver, L.P., Manchester, M., Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis. Sci. Rep., 1, 2011.
175. [175] HarrisJr, E.D., Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 322 (1990), 1277–1289.
176. [176] Yang, Z., Fujii, H., Mohan, S.V., Goronzy, J.J., Weyand, C.M., Phosphofructokinase deficiency impairs ATP generation autophagy, and redox balance in rheumatoid arthritis T cells. J. Exp. Med. 210 (2013), 2119–2134.
177. [177] Gleeson, P.A., Toh, B.H., Van Driel, I.R., Organ-specific autoimmunity induced by lymphopenia. Immunol. Rev. 149 (1996), 97–125.
178. [178] Ukaji, F., Kitajima, I., Kubo, T., Shimizu, C., Nakajima, T., Maruyama, I., Serum samples of patients with rheumatoid arthritis contain a specific autoantibody to denatured aldolase A in the osteoblast-like cell line, MG-63. Ann. Rheum. Dis. 58 (1999), 169–174.
179. [179] Saulot, V., Vittecoq, O., Charlionet, R., Fardellone, P., Lange, C., Marvin, L., et al. Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum. 46 (2002), 1196–1201.
180. [180] Schaller, M., Burton, D.R., Ditzel, H.J., Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat. Immunol. 2 (2001), 746–753.